Practice Management
Patients taking glucagon-like peptide-1 (GLP-1) drugs like semaglutide for diabetes may have a lower risk of opioid drug overdose, according to a new study led by National Institute on Drug Abuse Director Nora Volkow, MD, published in JAMA Network Open. Previous empirical studies and anecdotal reports of fewer drug cravings among individuals with type 2 diabetes and comorbid opioid use disorder who use semaglutide inspired the study. Because the GLP-1 drugs are relatively new, there …
Read More
A nationwide population-based study on prescribing trends published in the Annals of Internal Medicine found a significant increase in new users of GLP-1 receptor agonists who don’t have a diagnosis of type 2 diabetes. The proportion of new GLP-1 users with type 2 diabetes decreased from nearly 90% to about 70% from 2019 to 2023, according to a separate analysis of the findings in MedPage Today. Meanwhile, new users tend to be those prescribed the …
Read More
Drugmakers are developing new iterations of GLP-1 weight loss drugs that could result in fewer side effects. According to a news item in Becker’s Hospital Review, 27 GLP-1 drugs are in development, but the majority of the data is based on animal studies or early-stage human trials. In one example, researchers are optimistic about the experimental drug petrelinitide, which was shown to reduce body weight by an average of nearly 9% at 16 weeks. It …
Read More